Latest filing published 12 Mar 2026 for Ironwood Pharmaceuticals INC. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Minardo John in Ironwood Pharmaceuticals Inc, where the filings describe the role as senior executive. We count 16 filings; the first trade dates from 2 August 2021 and the latest from 10 March 2026.
The open-market record consists of 8 sales worth €1.1M, with no purchase. Outside the open market, there are 7 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 1 sale.
On 12 March 2026 came the latest disclosure, a share grant in Ironwood Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
16 of 16 declarations